



SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

October 2, 2026

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.

Presentation Details:

Title: [Improved Outcomes in Pediatric Sepsis-Associated \(SA\) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics \(SCD-PED\) Surveillance Registry \(SAVE\) with a Historical Cohort](#)

Authors: Nathan L. Kleinman, Stuart Goldstein, Rajit K. Basu, Theresa A. Mottes, David J. Askenazi, Stephen Gorga, Shina Menon, Matt S. Zinter, Keri A. Drake, David A. Zolezzi, Robert S. Gillespie, Sai Prasad N. Iyer, Emily Scribe, Kevin K. Chung

Abstract / Poster Number: TH-PO1291

Date & Time: October 22, 2026, from 10:00 a.m. to 12:00 p.m. MT

Location: Exhibit Hall A, Colorado Convention Center

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical's first commercial product, [QUELIMMUNE \(SCD-PED\)](#), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on [LinkedIn](#) or [X](#).

Contact:

IR@SEASTARMED.COM

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.